Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...

Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

If you want to know who really controls Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in ...

In the latest quarter, 4 analysts provided ratings for Y-mAbs Therapeutics (NASDAQ:YMAB), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics YMAB, expressing a variety of opinions spanning from bullish to bearish. The following table summarizes ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company valued at $460 million, has garnered attention from analysts for its innovative approach to cancer treatment, ...